Purple Biotech inks deal with Mor Research on cancer treatments

3 January 2023
biotech_research_vials_big

Israel-based clinical-stage company Purple Biotech (Nasdaq: PPBT) saw its shares edge up more than 4% to 53.10 shekels today, when it announced a research collaboration with Mor Research Applications (Mor), the technology transfer subsidiary of Clalit Healthcare Services (Clalit).

The agreement provides Purple Biotech first access to early-stage oncology product candidates owned by Mor. Additionally, the company will have the option to fund early development aiming both to in-license selected drug assets and to pursue their development and commercialization.

Clalit is Israel's largest Health Maintenance Organization (HMO), covering around half the population of Israel (52%). Clalit serves about 4.8 million members and operates 14 hospitals. The research conducted at these hospitals is now potentially available to Purple Biotech for in-licensing and clinical development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology